Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
Partnering with Personalis ensures you have a cutting-edge laboratory and team working alongside you in the fight against cancer. Our CAP-accredited, CLIA-certified laboratory is equipped with robotics for efficient scale-up, a custom Genomics Workflow Management System, and the latest sequencing technology including Illumina NovaSeq instrumentation to ensure your results are delivered with reliable high-quality and rapid timelines.
*Closed on the following holidays in 2025:
Personalis has obtained licenses from the states listed below, and therefore is licensed to accept samples from all states except New York. In New York, Personalis is licensed to provide the ACE Clinical Exome Test.
Here’s a step-by step-guide to our process.
Personalis is a genomics company transforming the development of next generation cancer therapies and diagnostics by providing more comprehensive molecular data about each patient’s tumor. Personalis is committed to achieving Customer Requirements and to complying with applicable Quality Standards and Regulatory Requirements in the area of Precision Medicine.
